Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 8.42% is 26% below its 5-year average of 11.43%, near the low end of its 5-year range (8.42%–13.30%).
17.97% below its 12-month average of 10.27%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.16%.
RETURN ON ASSETS (ROA)
8.42%
RETURN ON ASSETS (ROA) AVG TTM
10.27%
RETURN ON ASSETS (ROA) AVG 3Y
11.53%
RETURN ON ASSETS (ROA) AVG 5Y
11.43%
RETURN ON ASSETS (ROA) AVG 10Y
12.78%
RETURN ON ASSETS (ROA) AVG 15Y
12.89%
RETURN ON ASSETS (ROA) AVG 20Y
13.98%
CURRENT VS TTM AVG
-17.97%
CURRENT VS 3Y AVG
-26.96%
CURRENT VS 5Y AVG
-26.31%
CURRENT VS 10Y AVG
-34.10%
CURRENT VS 15Y AVG
-34.67%
CURRENT VS 20Y AVG
-39.77%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+126.12%
vs the sector median at left
Utah Medical Products, Inc.
Market Cap
$235.83M
Return on Assets (ROA)
8.42%
TTM Avg
10.27%
3Y Avg
11.53%
5Y Avg
11.43%
Market Cap
$236.23M
Return on Assets (ROA)
-8.48%
TTM Avg
-16.43%
3Y Avg
-20.20%
5Y Avg
-32.31%
Market Cap
$236.58M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$236.83M
Return on Assets (ROA)
-49.04%
TTM Avg
-75.08%
3Y Avg
-74.95%
5Y Avg
-71.96%
Market Cap
$234.20M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$237.72M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$238.13M
Return on Assets (ROA)
-8.99%
TTM Avg
-7.90%
3Y Avg
-14.69%
5Y Avg
-13.78%
Market Cap
$232.74M
Return on Assets (ROA)
-1.57%
TTM Avg
17.43%
3Y Avg
19.75%
5Y Avg
24.82%
Market Cap
$225.89M
Return on Assets (ROA)
-29.12%
TTM Avg
-42.23%
3Y Avg
-51.88%
5Y Avg
-48.35%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Utah Medical Products, Inc. (UTMD) | $235.83M | 8.42% | 10.27% | 11.53% | 11.43% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.23M | -8.48% | -16.43% | -20.20% | -32.31% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | -114.79% | -67.19% | -63.94% | -45.91% |
| Invivyd, Inc. (IVVD)vs › | $236.83M | -49.04% | -75.08% | -74.95% | -71.96% |
| InflaRx N.V. (IFRX)vs › | $234.20M | -23.88% | -71.64% | -51.89% | -47.09% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $237.72M | -244.25% | -369.36% | -230.97% | -157.86% |
| High Tide Inc. (HITI)vs › | $238.13M | -8.99% | -7.90% | -14.69% | -13.78% |
| SIGA Technologies, Inc. (SIGA)vs › | $232.74M | -1.57% | 17.43% | 19.75% | 24.82% |
| Biodesix, Inc. (BDSX)vs › | $225.89M | -29.12% | -42.23% | -51.88% | -48.35% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.12M | N/A | -14.72% | -16.00% | -18.82% |
ROA
8.4%
ROE
8.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 9.21% |
| 2024-12-31 | 11.32% |
| 2023-12-31 | 12.28% |
| 2022-12-31 | 13.30% |
| 2021-12-31 | 12.79% |
| 2020-12-31 | 9.66% |
| 2019-12-31 | 13.41% |
| 2018-12-31 | 18.60% |
| 2017-12-31 | 9.17% |
| 2016-12-31 | 15.84% |
| 2015-12-31 | 14.96% |
| 2014-12-31 | 14.03% |
| 2013-12-31 | 14.13% |
| 2012-12-31 | 13.22% |
| 2011-12-31 | 9.71% |
| 2010-12-31 | 14.58% |
| 2009-12-31 | 14.99% |
| 2008-12-31 | 18.56% |
| 2007-12-31 | 17.19% |
| 2006-12-31 | 18.49% |
| 2005-12-31 | 18.12% |
| 2004-12-31 | 24.77% |
| 2003-12-31 | 41.78% |
| 2002-12-31 | 30.64% |
| 2001-12-31 | 25.17% |
| 2000-12-31 | 21.13% |
| 1999-12-31 | 19.70% |
| 1998-12-31 | 15.31% |
| 1997-12-31 | 13.65% |
| 1996-12-31 | 30.45% |
